These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
116 related articles for article (PubMed ID: 12771513)
1. Development of synthetic pan-selectin antagonists: a new treatment strategy for chronic inflammation in asthma. Aydt E; Wolff G Pathobiology; 2002-2003; 70(5):297-301. PubMed ID: 12771513 [TBL] [Abstract][Full Text] [Related]
2. Targeting selectins for the treatment of respiratory diseases. Romano SJ; Slee DH Curr Opin Investig Drugs; 2001 Jul; 2(7):907-13. PubMed ID: 11757789 [TBL] [Abstract][Full Text] [Related]
3. Bimosiamose, an inhaled small-molecule pan-selectin antagonist, attenuates late asthmatic reactions following allergen challenge in mild asthmatics: a randomized, double-blind, placebo-controlled clinical cross-over-trial. Beeh KM; Beier J; Meyer M; Buhl R; Zahlten R; Wolff G Pulm Pharmacol Ther; 2006; 19(4):233-41. PubMed ID: 16140027 [TBL] [Abstract][Full Text] [Related]
4. Selectin antagonists : therapeutic potential in asthma and COPD. Romano SJ Treat Respir Med; 2005; 4(2):85-94. PubMed ID: 15813660 [TBL] [Abstract][Full Text] [Related]
5. Cell adhesion antagonists: therapeutic potential in asthma and chronic obstructive pulmonary disease. Woodside DG; Vanderslice P BioDrugs; 2008; 22(2):85-100. PubMed ID: 18345706 [TBL] [Abstract][Full Text] [Related]
7. Blockade of cell adhesion by a small molecule selectin antagonist attenuates myocardial ischemia/reperfusion injury. Onai Y; Suzuki J; Nishiwaki Y; Gotoh R; Berens K; Dixon R; Yoshida M; Ito H; Isobe M Eur J Pharmacol; 2003 Nov; 481(2-3):217-25. PubMed ID: 14642789 [TBL] [Abstract][Full Text] [Related]
8. Development of cell adhesion molecule antagonists as therapeutics for asthma and COPD. Vanderslice P; Biediger RJ; Woodside DG; Berens KL; Holland GW; Dixon RA Pulm Pharmacol Ther; 2004; 17(1):1-10. PubMed ID: 14643165 [TBL] [Abstract][Full Text] [Related]
9. Pan-selectin antagonism improves psoriasis manifestation in mice and man. Friedrich M; Bock D; Philipp S; Ludwig N; Sabat R; Wolk K; Schroeter-Maas S; Aydt E; Kang S; Dam TN; Zahlten R; Sterry W; Wolff G Arch Dermatol Res; 2006 Feb; 297(8):345-51. PubMed ID: 16362415 [TBL] [Abstract][Full Text] [Related]
10. Effects of the pan-selectin antagonist bimosiamose (TBC1269) in experimental human endotoxemia. Mayr FB; Firbas C; Leitner JM; Spiel AO; Reiter RA; Beyer D; Meyer M; Wolff G; Jilma B Shock; 2008 Apr; 29(4):475-82. PubMed ID: 18598003 [TBL] [Abstract][Full Text] [Related]
11. The anti-inflammatory effects of a selectin ligand mimetic, TBC-1269, are not a result of competitive inhibition of leukocyte rolling in vivo. Hicks AE; Abbitt KB; Dodd P; Ridger VC; Hellewell PG; Norman KE J Leukoc Biol; 2005 Jan; 77(1):59-66. PubMed ID: 15466915 [TBL] [Abstract][Full Text] [Related]
12. Inhibition of adhesion of human neutrophils and eosinophils to P-selectin by the sialyl Lewis antagonist TBC1269: preferential activity against neutrophil adhesion in vitro. Davenpeck KL; Berens KL; Dixon RA; Dupre B; Bochner BS J Allergy Clin Immunol; 2000 Apr; 105(4):769-75. PubMed ID: 10756228 [TBL] [Abstract][Full Text] [Related]
13. Anti-selectin therapy for the treatment of inflammatory diseases. Rossi B; Constantin G Inflamm Allergy Drug Targets; 2008 Jun; 7(2):85-93. PubMed ID: 18691137 [TBL] [Abstract][Full Text] [Related]